Bioptimus

The subsidiary of Google parent Alphabet plans to use its first round of external funding to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas.

Another company involved in using AI to repurpose failed drugs - as well as drugs that have already been approved - is BioXcel Therapeutics. Unlike Ignota, however, the company focuses on compounds that have already demonstrated safety in prior clinical trials, but have been discontinued by their developers for various other reasons.

A new National Academies report recommends ways for the U.S. to reap the benefits of artificial intelligence in biotechnology while minimizing risks that AI may be misused to develop harmful biological agents.

Beyond speed, AI has also helped reduce costs. Conventional methods required nearly $35,000 per genome analysis, but AI-driven models running on GPUs have lowered the cost to under $2,000, making high-quality genomic research more accessible.

Google has developed an AI tool to act as a virtual collaborator for biomedical scientists, the U.S. blue chip said on Wednesday.

Biotechnology innovations are revolutionizing healthcare with AI, data science, and automation, leading to more precise and personalized treatments.

Researchers at Harvard SEAS and NTT Research used machine-learning-directed optimization (ML-DO) to design biohybrid mini-rays that swim twice as efficiently as conventional biomimetic models, marking a breakthrough in biohybrid robotics.

Meta has developed a device that reconstruct entire sentences simply by reading neural signals — without the need of a brain implant.